- Author
- Maarten van den Berge, Bianca Beghé, Lies Lahousse (UGent) , Sami O. Simons, Lowie Vanfleteren and Leonardo Fabbri
- Organization
- Abstract
- This chapter focuses on the pharmacological treatment of stable COPD. The main treatments of stable COPD are initially short-acting or long-acting bronchodilators, comprising β-agonists (SABAs and LABAs) or antimuscarinics (SAMAs and LAMAs), preferably combined in a single-inhaler dual therapy (LABA/LAMA). A subset of patients may benefit from ICS added to LABA/LAMA treatment, preferably in a single-inhaler triple therapy (SITT; LABA/LAMA/ICS). These treatments improve symptoms and quality of life and reduce exacerbations. Since ICS have side-effects (e.g. pneumonia), they should be given only to patients with higher blood eosinophil counts (>100, preferably >300 cells·μL−1), and their benefits must be balanced with their risks. In patients not controlled by SITT, additional treatments are roflumilast, macrolide maintenance, and possibly dupilumab for eosinophilic COPD.
Downloads
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 704.71 KB
-
(...).jpg
- colophon/title page
- |
- UGent only
- |
- image/jpeg
- |
- 926.34 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01HS0MWBG5CC4PYSCZ02E57D8G
- MLA
- van den Berge, Maarten, et al. “Current Pharmacotherapy of COPD.” COPD in the 21st Century, edited by JA Wedzicha et al., European Respiratory Society, 2024, pp. 212–32.
- APA
- van den Berge, M., Beghé, B., Lahousse, L., Simons, S. O., Vanfleteren, L., & Fabbri, L. (2024). Current pharmacotherapy of COPD. In J. Wedzicha, J. Allinson, & P. Calverley (Eds.), COPD in the 21st Century (pp. 212–232). European Respiratory Society.
- Chicago author-date
- Berge, Maarten van den, Bianca Beghé, Lies Lahousse, Sami O. Simons, Lowie Vanfleteren, and Leonardo Fabbri. 2024. “Current Pharmacotherapy of COPD.” In COPD in the 21st Century, edited by JA Wedzicha, JP Allinson, and PMA Calverley, 212–32. European Respiratory Society.
- Chicago author-date (all authors)
- van den Berge, Maarten, Bianca Beghé, Lies Lahousse, Sami O. Simons, Lowie Vanfleteren, and Leonardo Fabbri. 2024. “Current Pharmacotherapy of COPD.” In COPD in the 21st Century, ed by. JA Wedzicha, JP Allinson, and PMA Calverley, 212–232. European Respiratory Society.
- Vancouver
- 1.van den Berge M, Beghé B, Lahousse L, Simons SO, Vanfleteren L, Fabbri L. Current pharmacotherapy of COPD. In: Wedzicha J, Allinson J, Calverley P, editors. COPD in the 21st Century. European Respiratory Society; 2024. p. 212–32.
- IEEE
- [1]M. van den Berge, B. Beghé, L. Lahousse, S. O. Simons, L. Vanfleteren, and L. Fabbri, “Current pharmacotherapy of COPD,” in COPD in the 21st Century, J. Wedzicha, J. Allinson, and P. Calverley, Eds. European Respiratory Society, 2024, pp. 212–232.
@incollection{01HS0MWBG5CC4PYSCZ02E57D8G, abstract = {{This chapter focuses on the pharmacological treatment of stable COPD. The main treatments of stable COPD are initially short-acting or long-acting bronchodilators, comprising β-agonists (SABAs and LABAs) or antimuscarinics (SAMAs and LAMAs), preferably combined in a single-inhaler dual therapy (LABA/LAMA). A subset of patients may benefit from ICS added to LABA/LAMA treatment, preferably in a single-inhaler triple therapy (SITT; LABA/LAMA/ICS). These treatments improve symptoms and quality of life and reduce exacerbations. Since ICS have side-effects (e.g. pneumonia), they should be given only to patients with higher blood eosinophil counts (>100, preferably >300 cells·μL−1), and their benefits must be balanced with their risks. In patients not controlled by SITT, additional treatments are roflumilast, macrolide maintenance, and possibly dupilumab for eosinophilic COPD.}}, author = {{van den Berge, Maarten and Beghé, Bianca and Lahousse, Lies and Simons, Sami O. and Vanfleteren, Lowie and Fabbri, Leonardo}}, booktitle = {{COPD in the 21st Century}}, editor = {{Wedzicha, JA and Allinson, JP and Calverley, PMA}}, isbn = {{9781849841757}}, issn = {{2312-508X}}, language = {{eng}}, pages = {{212--232}}, publisher = {{European Respiratory Society}}, series = {{ERS Monograph}}, title = {{Current pharmacotherapy of COPD}}, url = {{https://books.ersjournals.com/content/copd-in-the-21st-century}}, year = {{2024}}, }